PHVS
Pharvaris N.V.Healthcare · $2.2B market cap
Verdict
We can't put a fair value on PHVS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow PHVS
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds PHVS. Who we track
Insider activity
Since Sep 8, 2026: no open-market purchases, 3 sales worth $1.2M and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Glassman Robert
director · 2026-09-15
Sold
$332K
Glassman Robert
director · 2026-09-09
Sold
$300K
Lu Peng
President · 2026-09-08
Sold
$610K
Other filings
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works